Macro Group Pharmaceuticals (Macro Capital) S.A.E Sustainability Profile
Macro Group Pharmaceuticals (Macro Capital) S.A.E., headquartered in Egypt, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of innovative healthcare solutions. Founded in 2016, the company has rapidly established itself as a leader in the production of high-quality injectable and topical pharmaceuticals, catering to both local and international markets. With a strong focus on research and development, Macro Group Pharmaceuticals offers a diverse portfolio of products, including advanced formulations that address various medical needs. The company is recognised for its commitment to quality and safety, ensuring that its offerings meet stringent regulatory standards. As a result, Macro Group has achieved significant market presence and is well-regarded for its contributions to the healthcare sector in Egypt and beyond.
DitchCarbon Score
How does Macro Group Pharmaceuticals (Macro Capital) S.A.E's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Macro Group Pharmaceuticals (Macro Capital) S.A.E's score of 5 is lower than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Macro Group Pharmaceuticals (Macro Capital) S.A.E's reported carbon emissions
Macro Group Pharmaceuticals (Macro Capital) S.A.E, headquartered in Egypt, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As a result, Macro Group Pharmaceuticals appears to be in the early stages of establishing its climate commitments and emissions reduction strategies. Without inherited data from a parent company or industry benchmarks, the organisation has not yet set specific targets for emissions reduction or sustainability initiatives. In the context of the pharmaceutical industry, companies are increasingly focusing on reducing their carbon footprints and committing to science-based targets. However, without concrete data or commitments, it is unclear how Macro Group Pharmaceuticals aligns with these industry trends.
How Carbon Intensive is Macro Group Pharmaceuticals (Macro Capital) S.A.E's Industry?
How Carbon Intensive is Macro Group Pharmaceuticals (Macro Capital) S.A.E's Location?
Macro Group Pharmaceuticals (Macro Capital) S.A.E's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Macro Group Pharmaceuticals (Macro Capital) S.A.E has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
